FrancophonIA/ELRC3.0 huggingface dataset:
English: Rheumocam contains the active substance meloxicam and is a generic medicine.
Estonian: Rheumocam sisaldab toimeainena meloksikaami ja on geneeriline ravim.
English: The formulation to use depends on the animal and the condition being treated.
Estonian: Kasutatav ravimvorm oleneb loomaliigist ja ravitavast seisundist.
English: Rheumocam contains meloxicam, which belongs to a class of medicines called non-steroidal antiinflammatory drugs (NSAIDs).
Estonian: Rheumocam sisaldab meloksikaami, mis kuulub mittesteroidsete põletikuvastaste ravimite (NSAID) klassi.
English: The withdrawal period is the time required after administration of the medicine before an animal can be slaughtered and the meat used for human consumption.
Estonian: Keeluaeg on alates ravimi manustamisest arvestatav aeg, mille jooksul ei tohi looma tappa ega tema liha inimtoiduks tarvitada.
English: In pigs, Rheumocam is used to reduce lameness and inflammation in non-infectious locomotor disorders (diseases that affect the ability to move), for the relief of post-operative pain after minor soft tissue surgery such as castration, and for supportive therapy together with appropriate antibiotic therapy in the treatment of diseases that occur after farrowing (giving birth) such as puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome).
Estonian: Sigadel kasutatakse Rheumocami mittenakkuslike lokomotoorikahäirete (liikumisvõimet piiravad haigused) korral lonkamise ja põletikusümptomite vähendamiseks, pehmete kudede operatsioonide, nt kastreerimisjärgse valu vähendamiseks ja poegimisjärgsete haiguste, nt poegimisjärgse sepsise (veremürgistuse) ja tokseemia (mastiidi-metriidi-agalaktia sündroom) toetavaks raviks koos sobiva antibiootikumraviga.
English: How is Rheumocam used?
Estonian: Kuidas Rheumocami kasutatakse?
English: What are the benefits and risks of Rheumocam?
Estonian: Milles seisneb Rheumocami kasulikkus ja mis riskid ravimiga kaasnevad?
English: Since Rheumocam is a generic medicine, studies have been conducted to determine that it is bioequivalent to the reference medicine, Metacam.
Estonian: Et Rheumocam on geneeriline ravim, piirdusid uuringud katsetega, milles näidati Rheumocami bioekvivalentsust võrdlusravimiga Metacam.
English: How does Rheumocam work?
Estonian: Kuidas Rheumocam toimib?
English: Rheumocam can only be obtained with a prescription.
Estonian: Rheumocam on retseptiravim.
English: How has Rheumocam been studied?
Estonian: Kuidas Rheumocami uuriti?
English: In dogs, Rheumocam is used to reduce post-operative pain and inflammation following orthopaedic (e.g. fracture operation) and soft tissue surgery.
Estonian: Koertel kasutatakse Rheumocami operatsioonijärgse valu ja põletiku leevendamiseks pärast ortopeedilisi (nt luumurru) ja pehmete kudede operatsioone.
English: In cats, Rheumocam is used to reduce post-operative pain and inflammation after ovariohysterectomy (spaying operation), orthopaedic and minor soft tissue surgery.
Estonian: Kassidel kasutatakse Rheumocami operatsioonijärgse valu ja põletiku leevendamiseks pärast steriliseerimist (munasarjade ja emaka eemaldamist), ortopeedilisi operatsioone ja väikesi pehmete kudede operatsioone.
English: Rheumocam is available as granules, an oral (taken by mouth) suspension, chewable tablets and a solution for injection.
Estonian: Rheumocami turustatakse graanulite, suukaudse suspensiooni, närimistablettide ja süstelahusena.
English: In cattle, Rheumocam is used together with appropriate antibiotic therapy, to reduce clinical signs of acute respiratory infection (infection of the lungs and airways).
Estonian: Veistel kasutatakse Rheumocami ägeda respiratoorse infektsiooni (kopsude ja hingamisteede nakkuse) kliiniliste sümptomite vähendamiseks koos sobiva antibiootikumraviga.
English: It can be used as supportive therapy in the treatment of acute mastitis (inflammation of the udder), in combination with antibiotics.
Estonian: Rheumocami tohib kasutada ägeda mastiidi (udarapõletiku) toetava ravina koos antibiootikumidega.
English: Moreover, it is used to lessen inflammation and pain in acute and chronic musculo-skeletal disorders.
Estonian: Rheumocami kasutatakse ka põletiku ja valu leevendamiseks ägedate ja krooniliste luu- ja lihaskonna vaevuste korral.
English: In horses, Rheumocam is used to reduce pain associated with colic (abdominal pain) and to lessen inflammation and relieve pain in acute and chronic musculo-skeletal disorders (disorders affecting the muscles and bones).
Estonian: Hobustel kasutatakse Metacami voolmete (kõhuvalu) ning põletiku ja valu leevendamiseks ägedate ja krooniliste luu- ja lihaskonna vaevuste korral.
English: Why is Rheumocam authorised in the EU?
Estonian: Rheumocami Euroopa Liidus heakskiitmise põhjused
English: Specific interactions were not investigated.
Estonian: Konkreetseid koostoimeid ei uuritud.
English: Some dogs (less than 10%) experienced repeated vomiting (i.e. more than once every 20 days on average).
Estonian: Mõnedel koertel (vähem kui 10%) esines korduvat oksendamist (s.t keskmiselt rohkem kui üks kord 20 päeva vältel).
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Slentrol on 13.04.2007.
Estonian: Euroopa Komisjon väljastas Slentroli müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 13.04.2007.
English: Dirlotapide
Estonian: Dirlotapiid
English: It is available in three pack sizes; 20 ml, 50 ml and 150 ml and supplied with appropriate dosing devices.
Estonian: Seda turustatakse kolme eri suurusega pakendis: 20 ml, 50 ml ja 150 ml, mis on varustatud ka sobivate annustamisvahenditega.
English: Two large field trials were conducted, one in Europe and one in the USA, in healthy dogs which had a bodyweight higher than recommended.
Estonian: Viidi läbi kaks suurt väliuuringut, üks Euroopas ja teine USAs, tervete koertega, kelle kehakaal oli soovitatud tasemest kõrgem.
English: This veterinary medicine has been developed especially for dogs and is not for use in humans.
Estonian: See veterinaarravim on välja töötatud spetsiaalselt koertele ega ole ette nähtud kasutamiseks inimestele.
English: Slentrol has been studied in a large number of dogs in both laboratory and field trials for up to one year.
Estonian: Slentroli uuriti paljudel koertel nii labori- kui välikatsetes kuni ühe aasta jooksul.
English: The medicine is administered to the dog for 2 weeks, and after the first 2 weeks the veterinarian will double the initial dose for a further 2 weeks.
Estonian: Ravimit manustatakse koerale esialgu kahe nädala jooksul ning pärast esimest kahte nädalat kahekordistab veterinaararst algse annuse veel kaheks nädalaks.
English: The product can be administered with or without food for up to 12 months.
Estonian: Ravimit võib manustada kuni 12 kuu vältel, koos toiduga või ilma.
English: The majority of the weight loss occurs as a result of appetite suppression.
Estonian: Suurem osa kaalulangusest tuleneb isu vähenemisest.
English: If a person accidentally takes the medicine, seek medical advice immediately and show the package leaflet or the label to a doctor.
Estonian: Kui inimene peaks seda ravimit juhuslikult alla neelama, tuleb pöörduda kohe arsti poole ning näidata pakendi infolehte või etiketti.
English: The dogs also received other medicines during the study as required, such as anti-inflammatory drugs (including NSAIDs), antimicrobials, parasiticides, vaccines, dietary supplements, vitamins, hormones and cardiovascular drugs.
Estonian: Koerad said uuringu jooksul vajaduse korral ka muid ravimeid, näiteks põletikuvastaseid ravimeid (sealhulgas mittesteroidseid põletikuvastaseid ravimeid), mikroobide ja parasiitide vastaseid ravimeid, vaktsiine, toidulisandeid, vitamiine, hormoone ning südame- ja veresoonkonna ravimeid.
English: Some dogs received Slentrol while the remainder received the medicine with the active substance removed (control group).
Estonian: Üks osa koertest sai Slentroli ja ülejäänud said ravimit, millest oli toimeaine eemaldatud (kontrollrühm).
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Slentrol excede the risks for the management of overweight and obesity in adult dogs and recommended that Slentrol be given a marketing authorisation.
Estonian: Veterinaarravimite komitee otsustas, et Slentroli kasulikkus täiskasvanud koerte ülekaalulisuse ja rasvumuse raviks on suurem kui sellega kaasnevad riskid, ning Slentrolile soovitati anda müügiluba.
English: It is to be used as part of an overall weight management programme which also includes appropriate dietary changes and exercise practice.
Estonian: Seda kasutatakse üldise kaalujälgimise programmi raames, mis hõlmab ka sobivaid muudatusi dieedis ja füüsilist koormust.
English: Certain medications, e.g. drugs that lower serum cholesterol or other serum lipids, or drugs that affect appetite and/or body weight, e.g. long-acting glucorticoids, were not permitted for use during the study.
Estonian: Teatud ravimeid, nt seerumi kolesteroolitaset või muude lipiidide sisaldust alandavaid ravimeid või isu ja/või kehakaalu mõjutavaid ravimeid, nt pika toimeajaga glükokortikoide ei lubatud uuringu ajal kasutada.
English: If accidental skin or eye contact occurs, flush immediately with lots of water.
Estonian: Juhuslikul nahale või silma sattumisel tuleb seda kohta kohe loputada rohke veega.
English: The treatment is an initial measure in an obesity management programme; it has to be combined with changes in diet, which must be continued after treatment is finished.
Estonian: Ravi on rasvumise vähendamise programmi esmane meede, mida tuleb rakendada koos dieedi muutmisega, ning muudetud dieediga tuleb jätkata ka pärast ravi lõppu.
English: Slentrol contains the active substance dirlotapide which helps to reduce weight in dogs.
Estonian: Slentrol sisaldab toimeainena dirlotapiidi, mis aitab koertel kaalus alla võtta.
English: What is the risk associated with Slentrol?
Estonian: Millised on Slentroliga kaasnevad riskid?
English: The weight lowering effect was up to 20 % after 6 months of therapy in the initial weight loss phase of treatment.
Estonian: Kehakaalu alandav toime oli ravi esimesel kaalualandamisetapil pärast 6-kuulist ravi kuni 20%.
English: What is Slentrol?
Estonian: Mis on Slentrol?
English: The active substance in Slentrol, dirlotapide, works in the gut by blocking a protein (the microsomal triglyceride transfer protein).
Estonian: Slentroli toimeaine dirlotapiid toimib soolestikus teatud valgu (mikrosoomi triglütseriidide kandevalgu) blokeerimise teel.
English: Following these initial 4 weeks of therapy, dogs should be weighed monthly during treatment with the product and dose adjustments are made monthly according to the weight loss achieved.
Estonian: Pärast esimest nelja ravinädalat tuleb edasise ravi käigus koera korra kuus kaaluda ning kohandada annust iga kuu vastavalt saavutatud kaalulangusele.
English: What is Slentrol used for?
Estonian: Milleks Slentroli kasutatakse?
English: Rebound weight gain was seen after treatment was completed.
Estonian: Pärast ravi lõppu täheldati kaalu tõusu.
English: This protein is normally involved in the absorption of fats from the diet. By blocking the protein Slentrol decreases the absorption of fats from the gut and this change in fat absorption has an appetite suppressant effect.
Estonian: Selle valgu blokeerimisega vähendab Slentrol rasvade imendumist soolestikust ning see muutus rasvade imendumises vähendab isu.
English: Slentrol at the recommended dose of 5 mg/ml and using the recommended treatment schedule reduced body weight in obese dogs when compared to the control group.
Estonian: Slentroli kasutamisel soovitatavas annuses 5 mg/ml ning järgides soovitatavat raviskeemi rasvunud koerte kehakaal võrreldes kontrollrühmaga vähenes.
English: For a full list of all side-effects reported with Slentrol, see the Package Leaflet.
Estonian: Slentroli kohta teatatud kõrvalnähtude täieliku loetelu leiate pakendi infolehelt.
English: How has Slentrol been studied?
Estonian: Kuidas Slentroli uuriti?
English: Slentrol is used in adult dogs that are overweight or obese, to help them lose weight.
Estonian: Slentroli kasutatakse ülekaalulistel või rasvunud täiskasvanud koertel, et aidata neil kaalus alla võtta.
English: Vomiting, sometimes accompanied by signs of lethargy, diarrhoea or softened faeces may occur during treatment.
Estonian: Ravi ajal võib esineda oksendamist, millega võivad mõnikord kaasneda letargia, kõhulahtisuse või rooja pehmenemise nähud.
English: Slentrol is an oral solution, colourless to pale yellow in colour.
Estonian: Slentrol on värvitu või kollaka värvusega suukaudne lahus.
English: What benefit has Slentrol shown during the studies?
Estonian: Milles seisneb uuringute põhjal Slentroli kasulikkus?
English: Other information about Slentrol:
Estonian: Muu teave Slentroli kohta
English: It is available as capsules (5 mg; 20 mg; 100 mg; 140 mg; 180 mg; 250 mg).
Estonian: Ravimit turustatakse kapslitena (5 mg, 20 mg, 100 mg, 140 mg, 180 mg ja 250 mg).
English: Temozolomide Accord should be taken without food.
Estonian: Temozolomide Accordi tuleb võtta ilma toiduta.
English: The full EPAR for Temozolomide Accord can be found can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Temozolomide Accordi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The name of the medicine was changed to Temozolomide Accord on 27 May 2015.
Estonian: Ravimi nimetus muudeti 27. mail 2015 Temozolomide Accordiks.
English: The European Commission granted a marketing authorisation valid throughout the EU for Temozolomide Hospira on 15 March 2010.
Estonian: Euroopa Komisjon andis Temozolomide Hospira müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 15. märtsil 2010.
English: • adults and children three years of age and over with malignant glioma such as glioblastoma multiforme or anaplastic astrocytoma, when the tumour has returned or got worse after standard treatment.
Estonian: • täiskasvanud ja vähemalt 3-aastased lapsed, kellel on pahaloomuline glioom, näiteks multiformne glioblastoom või anaplastiline astrotsütoom, kui kasvaja on standardravi järel taastunud või progresseerunud.
English: MTIC binds to the DNA of cells while they are reproducing, which stops cell division.
Estonian: MTIC seondub rakkude paljunemise ajal nende DNAga, mis peatab rakkude pooldumise.
English: The dose of Temozolomide Accord depends on body surface area (calculated using the patient's height and weight) and ranges from 75 to 200 mg per square metre, once a day.
Estonian: Temozolomide Accordi annus oleneb kehapindalast (arvutatakse patsiendi pikkuse ja kehamassi järgi) ning on 75-200 mg/m2 ööpäevas.
English: The dose and the number of doses depend on the type of tumour being treated, whether the patient has been treated before, whether Temozolomide Accord is being used alone or with other treatments, and how the patient responds to treatment.
Estonian: Annus ja annuste arv sõltuvad ravitava kasvaja liigist, varasemast ravist, sellest, kas Temozolomide Accordi kasutatakse ainsa raviviisina või koos teistega, ja patsiendi ravivastusest.
English: The Committee recommended that Temozolomide Accord be given marketing authorisation.
Estonian: Komitee soovitas anda Temozolomide Accordi müügiloa.
English: For more information about treatment with Temozolomide Accord, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Temozolomide Accordiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Temozolomide Accord is used to treat malignant glioma (brain tumours) in the following groups of patients:
Estonian: Temozolomide Accordi kasutatakse pahaloomulise glioomi (teatud ajukasvaja) ravimiseks järgmistel patsiendirühmadel:
English: 1 Previously known as Temozolomide Hospira.
Estonian: 1 Varasem nimetus Temozolomide Hospira.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Temozolomide Accord.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Because Temozolomide Accord is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Temozolomide Accord on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: Temozolomide Accord temozolomide
Estonian: Temozolomide Accord temosolomiid
English: Therefore, the CHMP's view was that, as for Temodal, the benefit outweighs the identified risk.
Estonian: Seetõttu arvas inimravimite komitee, et nagu ka Temodali korral, ületab Temozolomide Accordi kasulikkus sellega kaasnevad riskid.
English: This is a summary of the European Public Assessment Report (EPAR) for Temozolomide Accord.
Estonian: See on ravimi Temozolomide Accord Euroopa avaliku hindamisaruande kokkuvõte.
English: Temozolomide Accord is used on its own in these patients.
Estonian: Nendel patsientidel kasutatakse Temozolomide Accordi ainsa raviviisina.
English: This means that Temozolomide Accord is similar to a ‘reference medicine' already authorised in the European Union (EU) called Temodal.
Estonian: See tähendab, et Temozolomide Accord on sarnane võrdlusravimiga Temodal, millel juba on Euroopa Liidus müügiluba.
English: Temozolomide Accord is a ‘generic medicine'.
Estonian: Temozolomide Accord on geneeriline ravim.
English: The CHMP concluded that, in accordance with EU requirements, Temozolomide Accord has been shown to have comparable quality and to be bioequivalent to Temodal.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Temozolomide Accordi võrdväärne kvaliteet ja bioekvivalentsus ravimiga Temodal.
English: Other information about Temozolomide Accord:
Estonian: Muu teave Temozolomide Accordi kohta
English: Because Temozolomide Accord is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Temodal.
Estonian: Et Temozolomide Accord on geneeriline ravim, piirdusid uuringud katsetega, milles näidati Temozolomide Accordi bioekvivalentsust võrdlusravimiga Temodal.
English: • adults with newly diagnosed glioblastoma multiforme (an aggressive type of brain tumour).
Estonian: • täiskasvanud, kellel on äsja diagnoositud multiformne glioblastoom (agressiivse kuluga teatud ajukasvaja liik); Temozolomide Accordi kasutatakse esialgu koos kiiritusraviga ning seejärel ainsa raviviisina;
English: Temozolomide Accord is a cancer medicine that contains the active substance temozolomide.
Estonian: Temozolomide Accord on ravim, mis sisaldab toimeainena temosolomiidi.
English: Patients may also need to take medicines to prevent vomiting before taking Temozolomide Accord.
Estonian: Enne Temozolomide Accordi võtmist võib olla vaja võtta oksendamist ennetavaid ravimeid.
English: The active substance in Temozolomide Accord, temozolomide, belongs to a group of cancer medicines called alkylating agents.
Estonian: Temozolomide Accordi toimeaine temosolomiid kuulub alküleerivateks aineteks nimetatavate vähiravimite rühma.
English: Why has Temozolomide Accord been approved?
Estonian: Miks Temozolomide Accord heaks kiideti?
English: Treatment with Temozolomide Accord should be prescribed by a doctor with experience in the treatment of brain tumours.
Estonian: Ravi Temozolomide Accordiga tohib määrata üksnes ajukasvajate ravis kogenud arst.
English: What is Temozolomide Accord?
Estonian: Mis on Temozolomide Accord?
English: What are the benefit and risk of Temozolomide Accord?
Estonian: Milles seisneb Temozolomide Accordi kasulikkus ja mis riskid ravimiga kaasnevad?
English: How has Temozolomide Accord been studied?
Estonian: Kuidas Temozolomide Accordi uuriti?
English: How does Temozolomide Accord work?
Estonian: Kuidas Temozolomide Accord toimib?
English: What is Temozolomide Accord used for?
Estonian: Milleks Temozolomide Accordi kasutatakse?
English: How is Temozolomide Accord used?
Estonian: Kuidas Temozolomide Accordi kasutatakse?
English: In the body, temozolomide is converted to another compound called MTIC.
Estonian: Organismis muundub temosolomiid 5-(3-metüül-1-triaseno-)-imidasool-4karboksamiidiks (MTIC).
English: • if you have an active infection which your doctor thinks is important.
Estonian: • kui teil on aktiivne infektsioon, mida teie arst peab oluliseks.
English: Always use this medicine exactly as your doctor has told you.
Estonian: Kasutage seda ravimit alati nagu arst on teile selgitanud.
English: • if you have long-term or repeated infections.
Estonian: • kui teil on pikaajaline või korduvad infektsioonid.
English: Your doctor will decide if and when you may restart the treatment.
Estonian: Teie arst otsustab, kas ja millal võite raviga uuesti alustada.
English: Date of first authorisation: 15 January 2015 Date of latest renewal: 03 September 2019
Estonian: Müügiloa esmase väljastamise kuupäev: 15.jaanuar 2015 Müügiloa viimase uuendamise kuupäev: 3. september 2019
English: • if you have tuberculosis.
Estonian: • kui teil on tuberkuloos.
English: DAS28-CRP Week 16
Estonian: DAS28-CRP 16. nädal
English: Your doctor will regularly monitor your condition to check that the treatment is having the desired effect.
Estonian: Teie arst jälgib regulaarselt teie seisundit, et teha kindlaks, kas ravil on soovitud tulemus.
English: These improvements were maintained for 52 weeks (studies 1 and 2).
Estonian: Täheldatud paranemine püsis 52 nädala jooksul (uuringud 1 ja 2).
English: You may see a small air bubble, which is normal.
Estonian: Te võite näha väikest õhumulli, mis on normaalne.
English: • if you are taking, have recently taken or might take any other medicines.
Estonian: • kui te võtate, olete hiljuti võtnud või kavatsete võtta mis tahes muid ravimeid.
English: Patients in these studies had a diagnosis of PsA of at least five years.
Estonian: Nendes uuringutes osalenud patsientidel oli PsA diagnoos olnud vähemalt 5 aastat.
English: Hold the syringe as shown.
Estonian: Hoidke süstlit nagu näidatud.
English: • burning sensation when passing urine.
Estonian: • põletav tunne urineerimisel.
English: The number of PsA patients with axial involvement was too small to allow meaningful assessment.
Estonian: Aksiaalse haaratusega PsA patsientide arv oli liiga väike, et võimaldada tähendusrikast hindamist.
English: The preparation time from piercing the stopper until end of reconstitution takes 20 minutes on average and should not exceed 90 minutes.
Estonian: Valmistamisaeg korgi läbistamisest kuni täieliku lahustumiseni kestab keskmiselt 20 minutit ja ei tohi ületada 90 minutit.
English: All patients were followed for up to 52 weeks following first administration of study treatment.
Estonian: Kõiki patsiente jälgiti kuni 52 nädalat pärast uuringuravi esimest manustamist.
English: Week 24 data are presented in Table 6.
Estonian: Tabelis 6 on toodud 24. nädala andmed.
English: The safety and efficacy of Cosentyx in children below the age of 18 years have not yet been established.
Estonian: Lapsed Cosentyxi ohutus ja efektiivsus lastel vanuses alla 18 aasta ei ole tõestatud.
English: Improvements were shown in all components of the ACR scores, including patient assessment of pain.
Estonian: Paranemist täheldati ACR skooride kõigi komponentide, kaasa arvatud patsiendi poolt valule antud hinnangu osas.
English: • Never try to reuse your pen.
Estonian: • Ärge kunagi proovige uuesti kasutada pen-süstlit.
English: The following information is intended for medical or healthcare professionals only.
Estonian: Järgmine teave on ainult meditsiini- või tervishoiutöötajatele: